February 1, 2023
1:00 PM – 2:00 PM (ET)
Speakers from AbbVie, the National Institutes of Health, the National Rare Disease Organization, NYU Grossman School of Medicine, and Verily share insights on how medical innovation is disrupting policy—and what’s needed next.
Many groundbreaking innovations are reshaping how we prevent, diagnose, treat and manage all medical conditions. Advances in RNA production and delivery to cells have enabled the development of mRNA vaccines with a wide range of applications from COVID to cancer. Although still in its infancy, implanted brain-computer interface technology is bringing new hope to the 5.4 million paralyzed Americans and restoring voluntary motor impulses to even those suffering from severe paralysis. Cell and gene therapies are creating a paradigm shift for people with hereditary and degenerative diseases, moving us beyond treating symptoms to repairing the body. It has shown potential to improve human health, predict the spread of infectious diseases, and enhance drug development. In fact, it made headlines when Insilico Medicine announced the world’s first Phase 1 clinical trial of a drug developed from scratch using AI.
These examples are just the tip of the iceberg. Breakthrough technologies and treatments are propelling us into a new era of medicine, offering exciting possibilities to patients who seemed hopeless just a few years ago. But will our healthcare policy landscape change as fast as the scientific landscape? Is our regulatory framework keeping up with the realities of the new healthcare landscape? Manatt, NYU In a new webinar by Law, NYU Wagner, a panel of thought leaders from across the healthcare ecosystem will discuss the opportunities and challenges of medical innovation and the impact of scientific disruption on healthcare policy with industry, regulatory, physician and patient point of view.click here Register for free. Main topics are:
- A review of current policies and regulations governing medical innovation
- How scientific advances are disrupting health policy and the changes needed to accommodate the next generation of treatments and technologies
- A discussion of clinical trial processes and practical and ethical issues related to access to investigational products
- Balancing Safety and Innovation, and the Challenge of Accelerating Approvals While Protecting Patients
- Next Steps – How New Policies Will Transform the Translational Science Process to Bring New Treatments and Treatments to Patients Faster
Even if you can’t join the live program, please click here Register now Rethinking healthcare: Can policy keep pace with scientific progress?— and receive a link to view the webinar on demand.
The PS webinar will provide a “first look” at the unique, interdisciplinary perspectives offered by the groundbreaking NYU Law + NYU Wagner Master of Science in Health Law and Strategy program created in collaboration with Manatt Health.Click for more information here.
- Charles CrippelFaculty Co-Director, Master of Science in Health Law and Strategy, and NYU Professor of Law Practice
- Amy AbernethyMD, Ph.D., President, Clinical Research Platform, Verily
- Alison Bateman HouseMPH, Ph.D., Assistant Professor, Department of Population Health, NYU Grossman School of Medicine
- Christopher BoonePh.D., Vice President, Global Head of HEOR, AbbVie, Inc.
- Joni LutherPh.D., National Institutes of Health, Director, National Center for Advancing Translational Sciences
- Heidi RossVice President, Policy and Regulatory Affairs, National Rare Disease Organization (NORD)
- Rachel SherPartner, Manatt Health
Due to accessibility issues, if you would like to receive an audio transcript of this webinar, please email [email protected]